[go: up one dir, main page]

MX2017012308A - Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b. - Google Patents

Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b.

Info

Publication number
MX2017012308A
MX2017012308A MX2017012308A MX2017012308A MX2017012308A MX 2017012308 A MX2017012308 A MX 2017012308A MX 2017012308 A MX2017012308 A MX 2017012308A MX 2017012308 A MX2017012308 A MX 2017012308A MX 2017012308 A MX2017012308 A MX 2017012308A
Authority
MX
Mexico
Prior art keywords
thienouracile
heterocyclylmethyl
adenosine
antagonists
receptor
Prior art date
Application number
MX2017012308A
Other languages
English (en)
Inventor
Kosemund Dirk
Härter Michael
Delbeck Martina
Kalthof Bernd
Lustig Klemens
Süssmeier Frank
Wasnaire Pierre
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2017012308A publication Critical patent/MX2017012308A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente solicitud se refiere a derivados novedosos de tieno[2,3-d]pirimidina-2,4-diona ("tienouracilo") que presentan un tipo particular de sustituyente (azaheterociclil)metilo, a procesos para la preparación de los mismos, al uso de los mismos por sí solos o en combinaciones para tratar y/o prevenir enfermedades y al uso de los mismos para producir medicamentos para tratar y/o prevenir enfermedades, especialmente para tratar y/o prevenir trastornos pulmonares y cardiovasculares y cáncer.
MX2017012308A 2015-03-26 2016-03-21 Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b. MX2017012308A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15161165 2015-03-26
EP15174566 2015-06-30
EP15184732 2015-09-10
PCT/EP2016/056106 WO2016150901A1 (de) 2015-03-26 2016-03-21 Heterocyclylmethyl-thienouracile als antagonisten des adenosin-a2b-rezeptors

Publications (1)

Publication Number Publication Date
MX2017012308A true MX2017012308A (es) 2018-01-26

Family

ID=55586319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012308A MX2017012308A (es) 2015-03-26 2016-03-21 Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b.

Country Status (24)

Country Link
US (1) US10428083B2 (es)
EP (1) EP3274352B1 (es)
JP (1) JP2018509443A (es)
KR (1) KR20170131540A (es)
CN (1) CN107646035A (es)
AU (1) AU2016236272A1 (es)
BR (1) BR112017020317A2 (es)
CA (1) CA2980646A1 (es)
CL (1) CL2017002390A1 (es)
CO (1) CO2017009656A2 (es)
CR (1) CR20170437A (es)
CU (1) CU20170123A7 (es)
DO (1) DOP2017000212A (es)
EA (1) EA201792134A1 (es)
EC (1) ECSP17064196A (es)
IL (1) IL254476A0 (es)
MX (1) MX2017012308A (es)
PE (1) PE20180116A1 (es)
PH (1) PH12017501758A1 (es)
SG (1) SG11201707577VA (es)
TN (1) TN2017000415A1 (es)
TW (1) TW201700480A (es)
UY (1) UY36586A (es)
WO (1) WO2016150901A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018041771A1 (de) 2016-09-02 2018-03-08 Bayer Pharma Aktiengesellschaft (1-methylcyclopropyl)methyl-substituierte thienouracile und ihre verwendung
PE20190474A1 (es) * 2016-09-23 2019-04-04 Bayer Ag Tienouracilos n3-ciclicamente sustituidos y uso de los mismos
JP6999112B2 (ja) * 2016-11-29 2022-02-04 国立研究開発法人産業技術総合研究所 ２，５－ビス（アミノメチル）フラン二ハロゲン化水素塩及びその製造方法並びに２，５－ビス（アミノメチル）フランの製造方法
AU2019367187A1 (en) 2018-10-24 2021-03-25 Leadxpro Ag Functionalized aminotriazines
JOP20210164A1 (ar) 2019-01-11 2023-01-30 Omeros Corp طرق وتركيبات علاج السرطان
WO2020172338A1 (en) * 2019-02-19 2020-08-27 Whitehead Institute For Biomedical Research Methods and agents for modulating mitochondrial nad levels
CN112500416B (zh) 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN111875615A (zh) * 2020-07-15 2020-11-03 济南大学 一种甲氧基苄脲类化合物及其用途
KR20230093251A (ko) 2020-09-10 2023-06-27 프리시릭스 엔.브이. Fap에 대한 항체 단편
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2036171A1 (es) 1970-07-21 1972-01-27
US6140325A (en) 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
TW276256B (es) * 1993-08-26 1996-05-21 Takeda Pharm Industry Co Ltd
WO1998038176A1 (en) 1997-02-26 1998-09-03 Hokko Chemical Industry Co., Ltd. 1-substituted 4-carbamoyl-1,2,4-triazol-5-one derivatives and herbicide
SE9702001D0 (sv) 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DK1107973T3 (da) 1998-08-28 2004-02-23 Astrazeneca Ab Hidtil ukendte thieno(2,3-D)pyrimidindioner, fremgangsmåde til deres fremstilling og anvendelse deraf i terapi
ES2254163T3 (es) 1999-04-09 2006-06-16 Cell Therapeutics, Inc. Compuestos terapeuticos para inhibir la señalizacion de la interleucina-12 y metodos para el uso de la misma.
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
ATE272642T1 (de) * 2000-05-04 2004-08-15 Astrazeneca Ab Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel
GB2363377B (en) 2000-06-14 2004-06-09 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones and therapeutic uses thereof
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002064598A1 (en) 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004014916A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US6890923B2 (en) 2002-12-16 2005-05-10 Astrazeneca Ab Compounds
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
EP1587811A1 (en) * 2003-01-17 2005-10-26 AstraZeneca AB Thienopyridazinones and their use in modulation of autoimmune disease
JP2008511683A (ja) 2004-09-02 2008-04-17 スリーエム イノベイティブ プロパティズ カンパニー ２−アミノ１ｈ−イミダゾ環構造および方法
WO2007103776A2 (en) 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
WO2008070529A2 (en) 2006-12-01 2008-06-12 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PH12013500055A1 (en) 2010-07-09 2017-08-23 Bayer Ip Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
RU2013117403A (ru) 2010-09-17 2014-10-27 Эррэй Биофарма Инк. Пиперидинил-замещенные лактамы как модуляторы gpr119
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012166700A2 (en) * 2011-05-29 2012-12-06 Lisanti Michael P Molecular profiling of a lethal tumor microenvironment
UA123760C2 (uk) 2011-11-11 2021-06-02 Гіліад Аполло, Ллс Сполука (варіанти) та композиція, що містить сполуку
US10085987B2 (en) * 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US20130287791A1 (en) * 2012-04-25 2013-10-31 C. Wilson Xu Modulation of histone h2b monoubiquitination and treatment of cancer
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
WO2014182943A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EA201600318A1 (ru) * 2013-10-07 2016-09-30 Байер Фарма Акциенгезельшафт Циклические тиеноурацилкарбоксамиды и их применение

Also Published As

Publication number Publication date
CN107646035A (zh) 2018-01-30
PE20180116A1 (es) 2018-01-18
CR20170437A (es) 2017-11-14
CU20170123A7 (es) 2018-02-08
BR112017020317A2 (pt) 2018-06-05
TW201700480A (zh) 2017-01-01
AU2016236272A1 (en) 2017-10-12
US10428083B2 (en) 2019-10-01
ECSP17064196A (es) 2017-10-31
EA201792134A1 (ru) 2018-03-30
CA2980646A1 (en) 2016-09-29
CL2017002390A1 (es) 2018-05-11
US20180065981A1 (en) 2018-03-08
CO2017009656A2 (es) 2018-01-16
UY36586A (es) 2016-10-31
JP2018509443A (ja) 2018-04-05
KR20170131540A (ko) 2017-11-29
WO2016150901A1 (de) 2016-09-29
IL254476A0 (en) 2017-11-30
PH12017501758A1 (en) 2018-04-11
SG11201707577VA (en) 2017-10-30
EP3274352B1 (de) 2019-01-02
DOP2017000212A (es) 2017-11-15
TN2017000415A1 (en) 2019-01-16
EP3274352A1 (de) 2018-01-31

Similar Documents

Publication Publication Date Title
PH12017501758A1 (en) Heterocyclymethyl-thienouracile as antagonists of the adenosine-a2b-receptor
TN2015000370A1 (en) Trifluormethyl-substituted ring-fused pyrimidines and use thereof
TN2014000298A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
PH12018500057A1 (en) Substituted oxopyridine derivatives
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
TN2015000434A1 (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
PH12013500055A1 (en) Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
PH12015502797A1 (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
JOP20200073A1 (ar) مركبات أميد إيميدازوبيريدين تحمل بدائل واستخداماتها
MX2019003351A (es) Tienouracilos n3-ciclicamente sustituidos y uso de los mismos.
TN2016000107A1 (en) Substituted phenylalanine derivatives
PH12018502359A1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and use thereof
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
MY196473A (en) 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof
WO2015165933A3 (de) Imidazo[1,2-a]pyridine als stimulatoren der löslichen guanylatcyclase zur behandlung von kardiovaskulären erkrankungen
TN2014000085A1 (en) Substituted annellated pyrimidine and the use thereof